Theranostics 2021, Vol. 11, Issue 9 4381 Ivyspring International Publisher Theranostics 2021; 11(9): 4381-4402. doi: 10.7150/thno.53652 Research Paper NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin Dong-Jie Li1,2,3*, Si-Jia Sun2,3*, Jiang-Tao Fu1*, Shen-Xi Ouyang2,3*, Qin-Jie Zhao,4 Li Su,5 Qing-Xi Ji,2,3 Di-Ynag Sun1, Jia-Hui Zhu2,3, Guo-Yan Zhang2,3, Jia-Wei Ma2,3, Xiu-Ting Lan,2,3 Yi Zhao,2,3 Jie Tong2,3, Guo-Qiang Li,1,6 Fu-Ming Shen2,3, Pei Wang1,2,3 1. Department of Pharmacology, School of Pharmacy, Second Military Medical University/Naval Medical University, Shanghai, China. 2. Department of Pharmacy, School of Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. 3. Tongji University School of Medicine, Shanghai, China. 4. Department of Organic Chemistry, School of Pharmacy, Second Military Medical University/Naval Medical University, Shanghai, China. 5. Institute of Translational Medicine, Shanghai University, Shanghai, China. 6. School of Life Science, East China Normal University, Shanghai, China. *These authors contributed equally to this work. Corresponding author: Prof. Pei Wang, Ph.D, MD, Department of Pharmacology, School of Pharmacy, Second Military Medical University/Naval Medical University, Shanghai, China. Tel: 86-21-81871276; E-mail:
[email protected]. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.